Covid -19.pptx

Lecture notes for medical students

1. Tips on using my ppt. You can freely download, edit, modify and put your name etc. Don’t be concerned about number of slides. Half the slides are blanks except for the title. First show the blank slides (eg. Aetiology ) > Ask students what they already know about ethology of today's topic. > Then show next slide which enumerates aetiologies. At the end rerun the show – show blank> ask questions > show next slide. This will be an ACTIVE LEARNING SESSION x three revisions. Good for self study also. See notes for bibliography.

2. Learning Objectives

3. Learning Objectives Introduction & History Relevant Anatomy, Physiology Aetiology Pathophysiology Pathology Classification Clinical Features Investigations Management Prevention Guidelines Take home messages

4. Introduction & History.

5. Introduction & History. Coronavirus disease 2019 (COVID-19) is defined as illness caused by a novel coronavirus now called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2; formerly called 2019-nCoV), First identified amid an outbreak of respiratory illness cases in Wuhan City, Hubei Province, China.  

6. Introduction & History. It was initially reported to the WHO on December 31, 2019. On January 30, 2020, the WHO declared the COVID-19 outbreak a global health emergency.  [2, 3]  On March 11, 2020, the WHO declared COVID-19 a global pandemic,

7. Aetiology

8. Aetiology Idiopathic Congenital/ Genetic Nutritional Deficiency/excess Traumatic Infections /Infestation Autoimmune Neoplastic (Benign/Malignant) Degenerative / lifestyle Iatrogenic Psychosomatic Poisoning/ Toxins/ Drug induced

9. Aetiology Idiopathic Congenital/Genetic Traumatic Infections /Infestation Autoimmune Neoplastic (Benign/Malignant) Degenerative Iatrogenic

10. Aetiology Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2; formerly called 2019-nCoV).

11. Aetiology of Aetiology

12. Aetiology of Aetiology Idiopathic Congenital/ Genetic Nutritional Deficiency/excess Traumatic Infections /Infestation Autoimmune Neoplastic (Benign/Malignant) Degenerative / lifestyle Iatrogenic Psychosomatic Poisoning/ Toxins/ Drug induced

13. Classification

14. Classification Asymptomatic Mild 81% Severe 14% Critical 5% ARDS Fatal 2.3%

15. Clinical Features

16. Clinical Features Demography Symptoms Signs Prognosis Complications

17. Demography

18. Demography Incidence & Prevalence Geographical distribution. Race Age Sex Socioeconomic status Temporal behaviour

19. Demography Incidence & Prevalence -

20. Demography Geographical distribution.

21. Demography Race.

22. Demography Age

23. Demography Sex

24. Demography Socioeconomic status

25. Demography Temporal behaviour

26. Symptoms

27. Symptoms Presentations of COVID-19 have ranged from asymptomatic/mild symptoms to severe illness and mortality. Mean incubation period to be 5.1 days 2 days to 2 weeks.

28. Symptoms Common Fever Cough Myalgia Fatigue Less-common Headache Sputum production Diarrhea Malaise Shortness of breath/ dyspnea Respiratory distress

29. Symptoms The most common serious manifestation of COVID-19 appears to be pneumonia. A complete or partial loss of the sense of smell ( anosmia ) has been reported as a potential history finding . Its clinical importance is questionable

30. Signs

31. Signs General Examination Systemic Examination Local Examination

32. Signs General Examination

33. Signs Systemic Examination

34. Signs Local Examination

35. Prognosis

36. Prognosis Morbidity Mortality rate 5 year survival in Malignancy

37. Investigations

38. Investigations Laboratory Studies Routine Special Imaging Studies Tissue diagnosis Cytology FNAC Histology Germ line Testing and Molecular Analysis Diagnostic Laparotomy.

39. Investigations Laboratory Studies Routine Special Imaging Studies Tissue diagnosis Cytology FNAC Histology

40. Investigations in Malignancy

41. Investigations in Malignancy For diagnosis For staging For Screening For Monitoring

42. Diagnostic Studies

43. Diagnostic Studies Imaging Studies X-Ray USG CT Angiography MRI Endoscopy Nuclear scan

44. Management

45. Management Early Oxygen support No Steroids Conservative fuid management. Monitoring Co- Morbidities. Early communication Early mechanical ventilation No Lopinavir Hydroxychloroquine Azithromycin Tocilizumab Empiric Antibiotics

46. Mechanical Ventilation Low tidal volume 4-8ml/Kg Low plateau pressure <30cm of water High PEEP Permissive hypercapnoea Deep sedation Prone Target Spo2 90%

47. Prevention

48. Prevention Screening Risk reduction

49. Mythbusters Myths Facts

50. Guidelines

51. Get this ppt in mobile Download Microsoft PowerPoint from play store. Open Google assistant Open Google lens. Scan qr code from next slide.

52. Get this ppt in mobile

53. Get my ppt collection https:// www.slideshare.net/drpradeeppande/edit_my_uploads https:// www.dropbox.com/sh/x600md3cvj85woy/AACVMHuQtvHvl_K8ehc3ltkEa?dl=0 https://www.facebook.com/doctorpradeeppande/?ref=pages_you_manage